EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-Malignant-Potential Adenocarcinoma: A Histological Category with a Significantly Better Prognosis than Other Solid Adenocarcinomas at IA Stage

Marco Chiappetta iD, Alessandra Cancellieri iD, Filippo Lococo iD, Elisa Meacci iD, Carolina Sassorossi iD, Maria Teresa Congedo iD, Qianqian Zhang iD, Diomira Tabacco, Isabella Sperduti, Stefano Margaritora

Current Oncology · 2025

DOI: 10.3390/curroncol32040217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Marco Chiappetta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery Unit, University "Magna Graecia", 88100 Catanzaro, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma, Adenocarcinoma of Lung. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Low-malignant-potential adenocarcinoma has been defined as a type of non-mucinous tumor, which has a total tumor size measuring ≤ 3 cm, exhibits ≥ 15% lepidic growth, lacks non-predominant high-grade patterns (≥10% cribriform, ≥5% micropapillary, ≥5% solid), has an absence of angiolymphatic or visceral pleural invasion, spread through air spaces (STAS), necrosis and >1 mitosis per 2 mm2. The aim of this study is to validate, with regard to cancer-specific survival (CSS) and disease-free survival (DFS), the proposed definition of LMP adenocarcinoma in an independent external cohort of lung adenocarcinoma patients having undergone surgical resection, and having presented with a long follow-up period.

Methods

Clinicopathological characteristics of patients who underwent lung resection for adenocarcinoma from 1 January 2005 to 31 December 2014 were retrospectively analyzed. Patients with ground-glass opacity (GGO) and part-solid tumors, minimally invasive adenocarcinoma (MIA), adenocarcinoma in situ (AIS), tumors ≥5 cm in size, nodal involvement and/or distant metastases, patients who underwent neoadjuvant treatment, and those who had an incomplete follow-up or a follow-up shorter than 60 months were excluded. The proposed criteria for low-malignant-potential adenocarcinoma (LMPA) were tumor size ≤ 3 cm, invasive size ≥ 0,5 cm, lepidic growth ≥ 15%, and absence of the following: mitosis (>1 per 2 mm2), mucinous subtype, angiolymphatic invasion, visceral pleural invasion, spread through air spaces (STAS) and tumor necrosis. End points were disease-free survival (DFS) and cancer-specific survival (CSS). The log-rank test was used to assess differences between subgroups.

Results

Out of 80 patients meeting the proposed criteria, 14 (17.5%) had the LMPA characteristics defined. The mean follow-up time was 67 ± 39 months. A total of 19 patients died, all in the non-LMPA category, and 33 patients experienced recurrence: 4 (28.5%) with LMPA and 29 (43.9%) with non-LMPA. Log-rank analysis showed 100% 10-year CSS for patients with LMPA and 77.4% for patients without LMPA, with this difference being statistically significant (p-value = 0.047). Univariate analysis showed a significant association with the cStage (AJCC eighth edition), both for CSS (p value = 0.005) and DFS (p-value = 0.003). LMPA classification did not show a statistically significant impact on CSS and DFS, likely due to the limited number of events (CSS p-value = 0.232 and DFS p-value = 0.213). No statistical association was found for CSS and DFS with pT, the number of resected nodes (< or >10) or the number of resected N2 stations (< or >2).

Conclusions

Our study confirmed the prognostic role of LMPA features, with a low risk of recurrence and a good CSS and DFS. The criteria for diagnosis are replicable and feasible for application. The clinical implications of these findings, such as pre-operative prediction and surveillance scheduling, may be the topic of future prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinomaAdenocarcinoma of LungHumansMaleFemaleMiddle AgedPrognosisAgedRetrospective StudiesNeoplasm StagingAdultDisease-Free Survival

Stichwörter der Autor:innen

NSCLCadenocarcinomalow-malignant-potential adenocarcinoma

Autor:innen und Institutionen

  • Thoracic Surgery Unit, University "Magna Graecia", 88100 Catanzaro, Italy.
  • UOC di Chirurgia Toracica, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
  • Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
  • Thoracic Surgery, UOC di Chirurgia Toracica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • UOC Chirurgia Toracica, Azienda Ospedaliero-Universitario Policlinico-San Marco, 95123 Catania, Italy.
  • Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

ORCID-Profile: Marco Chiappetta, Alessandra Cancellieri, Filippo Lococo, Elisa Meacci, Carolina Sassorossi, Maria Teresa Congedo, Qianqian Zhang

Zitieren

APA

Chiappetta, M., Cancellieri, A., Lococo, F., Meacci, E., Sassorossi, C., Congedo, M. T., Zhang, Q., Tabacco, D., Sperduti, I., & Margaritora, S. (2025). Low-Malignant-Potential Adenocarcinoma: A Histological Category with a Significantly Better Prognosis than Other Solid Adenocarcinomas at IA Stage. Current Oncology. https://doi.org/10.3390/curroncol32040217

Vancouver

Chiappetta M, Cancellieri A, Lococo F, Meacci E, Sassorossi C, Congedo MT, et al. Low-Malignant-Potential Adenocarcinoma: A Histological Category with a Significantly Better Prognosis than Other Solid Adenocarcinomas at IA Stage. Current Oncology. 2025. doi:10.3390/curroncol32040217

BibTeX
@article{Chiappetta2025,
  author = {Chiappetta, Marco and Cancellieri, Alessandra and Lococo, Filippo and Meacci, Elisa and Sassorossi, Carolina and Congedo, Maria Teresa and Zhang, Qianqian and Tabacco, Diomira and Sperduti, Isabella and Margaritora, Stefano},
  title = {Low-Malignant-Potential Adenocarcinoma: A Histological Category with a Significantly Better Prognosis than Other Solid Adenocarcinomas at IA Stage},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32040217}
}
Kostenlos starten →